• Title/Summary/Keyword: PFS

Search Result 318, Processing Time 0.035 seconds

A comparative analysis on market and technology in water industry (물산업 시장과 기술 비교분석)

  • Park, Imsu
    • Journal of Korean Society of Water and Wastewater
    • /
    • v.35 no.6
    • /
    • pp.437-454
    • /
    • 2021
  • This study investgates Korean water technology through the water market perspective and analyses its competitiveness. Based on the water technology classification, water technology competitiveness is analysed through the technological influence index and market dominance index which are based on the extracted water technology patents from the US, Europe, Korea, and Japan for the last decade. As a result, the Korean water technology patents were lack in influence and competitiveness in global market considering the large volume of patents. There are two most tech-influential industries in Korea; manufacturing industry consisting pipes, sterilization, disinfection, and advanced water purification equipment, and construction industry including seawater desalination and water resource development. Due to the domestic usage of the patents, the Korean water technology patents scored low in global market PFS(Patent Family Size) index compared to their CPP(Cites Per Patent) index. The study is meaningful in a way that the analysis on Korean water technology competitiveness using water technology classification system and patent analysis was conducted based on the perspective of the global water market.

A random forest-regression-based inverse-modeling evolutionary algorithm using uniform reference points

  • Gholamnezhad, Pezhman;Broumandnia, Ali;Seydi, Vahid
    • ETRI Journal
    • /
    • v.44 no.5
    • /
    • pp.805-815
    • /
    • 2022
  • The model-based evolutionary algorithms are divided into three groups: estimation of distribution algorithms, inverse modeling, and surrogate modeling. Existing inverse modeling is mainly applied to solve multi-objective optimization problems and is not suitable for many-objective optimization problems. Some inversed-model techniques, such as the inversed-model of multi-objective evolutionary algorithm, constructed from the Pareto front (PF) to the Pareto solution on nondominated solutions using a random grouping method and Gaussian process, were introduced. However, some of the most efficient inverse models might be eliminated during this procedure. Also, there are challenges, such as the presence of many local PFs and developing poor solutions when the population has no evident regularity. This paper proposes inverse modeling using random forest regression and uniform reference points that map all nondominated solutions from the objective space to the decision space to solve many-objective optimization problems. The proposed algorithm is evaluated using the benchmark test suite for evolutionary algorithms. The results show an improvement in diversity and convergence performance (quality indicators).

Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers

  • Baykara, Meltem;Buyukberber, Suleyman;Ozturk, Banu;Coskun, Ugur;Unsal, Diclehan Kilic;Demirci, Umut;Dane, Faysal;Kaplan, Muhammet Ali;Bora, Huseyin;Benekli, Mustafa
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.4
    • /
    • pp.2557-2561
    • /
    • 2013
  • Background: Chemoradiation (CRT) using cisplatin-based regimens has become the standard of care in the treatment of squamous cell head and neck cancers (SCHNC). The impact of taxanes as radiosensitizing agents with concurrent CRT regimens is unknown. We therefore retrospectively evaluated the efficacy and tolerability of a weekly cisplatin+docetaxel combination with CRT in locally advanced SCHNC. Methods: Sixty-six patients with locally advanced SCHNC (39.4% stage IV, 53% stage III, and 7.6% stage II) were assessed retrospectively. Total radiation dose to the PTV of gross disease (primary and/or node) was 70 Gy/35 fractions, 5 fractions per week. Minimum doses of 60 Gy and 50 Gy were administered to PTVs of elective high risk and low risk disease, respectively. Chemotherapy (CT) consisted of weekly cisplatin (20 $mg/m^2$)+docetaxel (20 $mg/m^2$) concurrently with RT. Results: The median age of the patients was 58 years (range, 32-77). Objective response rate was 83.3%. The 2-year progression-free survival (PFS) and overall survival (OS) were 75.7% and 78.3%, respectively. The most common grade 3 and 4 toxicities were mucositis (36.4%), nausea and vomiting (12.1%), neutropenia (4.5%). Conclusion: Weekly cisplatin and docetaxel concurrent with RT for locally advanced SCHNC was found tolerable with high efficacy.

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis

  • Wang, Kai;Peng, Hong-Ling;Li, Long-Kun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.11
    • /
    • pp.5665-5669
    • /
    • 2012
  • Background: The vascular endothelial growth factor (VEGF) mediates vasculogenesis and angiogenesis through promoting endothelial cell growth, migration and mitosis, and has involvement in cancer pathogenesis, progression and metastasis. However, the prognostic value of VEGF in patients with prostate cancer remains controversial. Objectives: The aim of our study was to evaluate the prognostic value of VEGF in prostate cancer, and summarise the results of related research on VEGF. Methods: In accordance with an established search strategy, 11 studies with 1,529 patients were included in our meta-analysis. The correlation of VEGF-expression with overall survival and progression-free survival was evaluated by hazard ratio, either given or calculated. Results: The studies were categorized by introduction of the author, demographic data in each study, prostate cancer-relatived information, VEGF cut-off value, VEGF subtype, methods of hazard ratio (HR) estimation and its 95% confidence interval (CI). High VEGF-expression in prostate cancer is a poor prognostic factor with statistical significance for OS (HR=2.32, 95%CI: 1.40-3.24). However, high VEGF-expression showed no effect on poor PFS (HR=1.30, 95%CI: 0.88-1.72). Using Begg's, Egger's test and funnel plots, we confirmed lack of publication bias in our analysis. Conclusion: VEGF might be regarded as a prognostic maker for prostate cancer, as supported by our meta-analysis. To achieve a more definitive conclusion enabling the clinical use of VEGF in prostate cancer, we need more high-quality interventional original studies following agreed research approaches or standards.

Metaplastic Breast Carcinoma: Case Series and Review of the Literature

  • Esbah, Onur;Turkoz, Fatma P.;Turker, Ibrahim;Durnali, Ayse;Ekinci, Ahmet S.;Bal, Oznur;Sonmez, Ozlem Uysal;Budakoglu, Burcin;Arslan, Ulku Y.;Oksuzoglu, Berna
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.9
    • /
    • pp.4645-4649
    • /
    • 2012
  • Metaplastic breast carcinoma (MpBC) is a rare disease entity, accounting for less than 1% of all breast carcinomas. Furthermore, it is a heterogenous disease with different subgroups, including malignant epithelial (carcinoma) and stromal (sarcoma) features. Here we evaluated, retrospectively, 14 female MpBC patients admitted to Ankara Oncology Training and Research Hospital between 2005 and 2011. Median age was 45.5 (range:16.0-76.0) and tumor size 57.5 mm (range: 20.0-80.0 mm). Histopathological subtypes were as follows: 5 carcinosarcoma, 5 squamous and 4 adenosquamous carcinoma. All but one with upfront lung metastasis, had their primary breast tumor operated. Axillary lymph nodes were involved in 64.3%. The most common sites of metastasis were lungs and brain. Chemotherapy including antracycline, taxane and even platinium was planned for adjuvant, neoadjuvant and palliative purposes in 9, 3 and 1 patient, respectively. Median cycles of chemotherapy was 6 (range:4-8). Median follow-up of the patients was 52 months (95%CI 10.4-93.6 month). Median 3 year progression free survival (PFS) and overall survival (OS) in this patients cohort were 33% and 56%, respectively. In conclusion, MpBC is a rare and orphan disease without standardized treatment approaches and the prognosis is poor so that larger studies to investigate different treatment schedules are urgently needed.

Staging with PET-CT in Patients with Locally Advanced Non Small Cell Lung Cancer is Superior to Conventional Staging Methods in Terms of Survival

  • Mutlu, Hasan;Buyukcelik, Abdullah;Erden, Abdulsamet;Aslan, Tuncay;Akca, Zeki;Kaya, Eser;Kibar, Mustafa;Seyrek, Ertugrul;Yavuz, Sinan;Calikusu, Zuleyha
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.6
    • /
    • pp.3743-3746
    • /
    • 2013
  • Background: Of patients with non small cell lung cancer (NSCLC), around one third are locally advanced at the time of diagnosis. Because only a proprotion of stage III patients can be cured by surgery, in order to improve the outcomes, sequential or concurrent chemoradiation, or concurrent chemoradiation with induction or consolidation is offered to the patients with locally advanced NSCLC. Today, PET combined with computerized tomography (PET-CT) is accepted as the most sensitive technique for detecting mediastinal lymph node and extracranial metastases from NSCLC. We aimed to compare PET-CT and conventional staging procedures for decisions regarding curative treatment of locally advanced NSCLC. Materials and Methods: A total of 168 consecutive patients were included from Acibadem Kayseri Hospital, Acibadem Adana Hospital and Kayseri Research and Training Hospital in this study. Results: While the median PFS was $13.0{\pm}1.9$ months in the PET-CT group, it was only $6.0{\pm}0.9$ in the others (p<0.001). The median OS values were $20.5{\pm}15.6$ and $11.5{\pm}1.5$ months, respectively (p<0.001). Discussion: As a result, we found that staging with PET CT has better results in terms of survival staging. This superiority leads to survival advantage in patients with locally advanced NSCLC.

Once-weekly Subcutaneous Administration of Bortezomib in Patients with Multiple Myeloma

  • Wang, Liang;Wang, Ke-Feng;Chang, Bo-Yang;Chen, Xiao-Qin;Xia, Zhong-Jun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.5
    • /
    • pp.2093-2098
    • /
    • 2015
  • In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile. However, whether once-weekly SC bortezomib can further reduce the incidence rate of peripheral neuropathy (PN) and not compromise the efficacy remains to be investigated. 25 patients of MM treated with once-weekly SC bortezomib were reviewed in this study. The median treatment cycles were 4 (range, 2-9 cycles). Complete response (CR) rate was 52%, ${\geq}$very good partial response (VGPR) rate was 72%, and ${\geq}$partial response (PR) rate was 84%. 1-year and 2-year PFS rate was 63.0% and 34.3%, respectively, and 2-year OS rate was 100%. Any grade of PN was reported in 9 patients (36.0%), with 7 patients (28.0%) had grade 1 PN, and 2 patients (8.0%) had grade 2 PN. No patients reported grade 3/4 PN in this cohort. In conclusion, once-weekly subcutaneous administration of bortezomib offers excellent efficacy with a further improved safety profile, especially with regard to PN. It needs to be validated in future prospective randomized trials.

Little Response of Cerebral Metastasis from Hepatocellular Carcinoma to Any Treatments

  • Han, Jung-Ho;Kim, Dong-Gyu;Park, Jung-Cheol;Chung, Hyun-Tai;Paek, Sun-Ha;Chung, Young-Seob
    • Journal of Korean Neurosurgical Society
    • /
    • v.47 no.5
    • /
    • pp.325-331
    • /
    • 2010
  • Objective : We retrospectively evaluated the survival outcome of patients with brain metastasis from hepatocellular carcinoma (HCC). Methods : Between 1991 and 2007, a total of 20 patients were diagnosed as having brain metastasis from HCC. The mean age of the patients was 55 ${\pm}$ 13 years, and 17 (85.0%) were men. Seventeen (85.0%) patients had already extracranial metastases. The median time from diagnosis of HCC to brain metastasis was 18.5 months. Fourteen (70.0%) patients had stroke-like presentation due to intracerebral hemorrhage (ICH). Ten (50.0%) patients had single or solitary brain metastasis. Among a total of 34 brain lesions, 31 (91.2%) lesions had the hemorrhagic components. Results : The median survival time was 8 weeks (95% CI, 5.08-10.92), and the actuarial survival rates were 85.0%, 45.0%, 22.5%, and 8.4% at 4, 12, 24, and 54 weeks. Age < 60 years, treatment of the primary and/or extracranial lesions, and recurrent ICH were the possible prognostic factors (p = 0.044, p < 0.001, and p = 0.111, respectively). The median progression-free survival (PFS) time was 3 months (95% CI, 0.95-5.05). Conclusion : The overall survival of the patients with brain metastasis from HCC was very poor with median survival time being only 8 weeks. However, the younger patients less than 60 years and/or no extracranial metastases seem to be a positive prognostic factor.

An Analysis of 6th Graders' Fraction Operations and Schemes (초등학교 6학년 학생들의 분수 조작 및 스킴 분석)

  • Han, Jeong Yee;Lee, Kwang Ho
    • School Mathematics
    • /
    • v.19 no.1
    • /
    • pp.59-75
    • /
    • 2017
  • This study analyzed the $6^{th}$ graders' constructions about fraction operations and schemes and figured out the relationships quantitatively between operations and schemes through the written test of 432 students. The results of this study showed that most of students could do partitioning operation well, however, there were many students who had difficulties on iterating operation. There were more students who constructed partitioning operation prior to iterating operation than the opposite. The rate of students who constructed high schemes was lower than that of students who constructed low schemes according to the hierarchy of fraction schemes. Especially, there were many students who construct partitive unit fraction scheme but not partitive fraction scheme, because they could compose unit fraction but not do iterating it. And there were the high correlations between fraction operations and schemes. Given these result, this paper suggests implications about the teaching and learning of fraction.

Clinical Study of Nimotuzumab Combined with Chemotherapy in the Treatment of Late Stage Gastric Cancer

  • Xu, Chong-De
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.23
    • /
    • pp.10273-10276
    • /
    • 2015
  • Objective: To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late gastric cancer. Methods: A total of 34 reoccurrence or metastatic patients with late stage gastric cancer who were confirmed by histopathology and/or cytology were selected and randomly divided into observational and control groups, of 17 cases each. Patients in the control group were treated with the standard DCF plan, while patients in observational group additionally received nimotuzumab. The short-term and long-term efficacy and adverse reactions in the 2 groups were followed. Results: The objective response rate (ORR) and disease control rate (DCR) were 64.7% (11/17) and 82.4% (14/17) in observational group and 25.0%(4/16) and 37.5%(6/16) in the control group(ORR and DCR between 2 groups, ${\chi}^2=5.2412$, P=0.0221 and ${\chi}^2=6.9453$, P=0.0084). The median progression-free survival (PFS) time and median overall survival (OS) time were 6.50 months and 12.50 months in observational group and 4.50 months and 8.25 months in the control group (P=0.0212; P=0.0255). The main toxic and side effects in the 2 groups were reduced leukocytes and hemoglobin, gastrointestinal reactions and hair loss and these were relieved after symptomatic treatment and nutrition support therapy. There were no differences in the occurrence of toxic and side effects between the 2 groups. Conclusions: Nimotuzumab combined with DCF plan is effective in treating late stage gastric cancer. A larger scale study is now warranted for confirmation of the findings.